Efficacy of neoadjuvant therapy with trastuzumab concurrent with anthracycline- and nonanthracycline-based regimens for HER2-positive breast cancer-Reference-Cited by-同舟云学术

Efficacy of neoadjuvant therapy with trastuzumab concurrent with anthracycline- and nonanthracycline-based regimens for HER2-positive breast cancer

Published:2011-09-27 Issue:9 Volume:118 Page:2385-2393
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Bayraktar Soley,Gonzalez-Angulo Ana M.,Lei Xiudong,Buzdar Aman U.,Valero Vicente,Melhem-Bertrandt Amal,Kuerer Henry M.,Hortobagyi Gabriel N.,Sahin Aysegul A.,Meric-Bernstam Funda

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference42 articles.

1. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy;Kuerer;J Clin Oncol.,1999

2. Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome;Sataloff;J Am Coll Surg.,1995

3. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer;Fisher;J Clin Oncol.,1998

4. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials;Early Breast Cancer Trialists' Collaborative Group;Lancet.,2005

5. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer;Piccart-Gebhart;N Engl J Med.,2005

Cited by 53 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-world evidence reported for clinical efficacy evaluation in European Public Assessment Reports of authorised targeted therapies for solid malignancies: a comprehensive review (2018-2022);ESMO Real World Data and Digital Oncology;2024-06

2. Pathological complete response and survival of HER2-positive invasive breast cancer following docetaxel, carboplatin, and trastuzumab neoadjuvant therapy: a Vietnamese experience;Oncology in Clinical Practice;2023-08-23

3. Eliminating Breast Surgery for Invasive Cancer with Exceptional Response to Neoadjuvant Systemic Therapy: Prospective Multicenter Clinical Trial Planned Initial Feasibility Endpoint;Journal of the American College of Surgeons;2023-03-01

4. The Value of Neoadjuvant Anthracycline-Based Regimens for HER2-Positive Breast Cancer: A Systematic Review and Meta-analysis Including 1366 Patients;Clinical Medicine Insights: Oncology;2023-01

5. Neoadjuvant chemotherapy with or without anthracyclines in combination with single HER2-targeted therapy in HER2-positive breast cancer;Cancer Treatment and Research Communications;2023